Validation of tumour models for use in anticancer nanomedicine evaluation: The EPR effect and cathepsin B-mediated drug release rate

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 417-427

  Duncan, Ruth ^a,e   Sat Klopsch, Yee Nee ^a   Burger, Angelika M ^b   Bibby, Michael C ^c   Fiebig, Heinz H ^b   Sausville, Edward A ^d  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b CHARLES RIVER LABORATORIES   (United States)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d UNIVERSITY OF MARYLAND   (United States)

^e CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Cathepsin B; EPR effect; Evans Blue; HPMA copolymer doxorubicin; Nanomedicines

Indexed keywords

CATHEPSIN B; COPOLYMER; DOXORUBICIN; EVANS BLUE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PACLITAXEL;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG RELEASE; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHATIC LEUKEMIA; MELANOMA; MOUSE; NANOMEDICINE; NEUROBLASTOMA; NONHUMAN; PANCREAS CARCINOMA; PERMEABILITY; PRIORITY JOURNAL; TUMOR LOCALIZATION; TUMOR MODEL; TUMOR VOLUME; VALIDATION PROCESS; XENOGRAFT;

ACRYLAMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CATHEPSIN B; CELL LINE, TUMOR; COLORING AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOXORUBICIN; EVANS BLUE; HUMANS; LEUKEMIA L1210; MICE; NANOTECHNOLOGY; PERMEABILITY; POLYGLUTAMIC ACID; POLYMERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880892472     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2209-7     Document Type: Article

References (43)

1. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688-701 (Pubitemid 44286001)
2. Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharmaceutics 8:2101-2141
3. Farrell D, Ptak K, Panaro NJ, Grodzinski P (2011) Nanotechnology-based cancer therapeutics-promise and challenge-lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm Res 28:273-278
4. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG (2011) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39-50
5. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res 6:6387-6392 (Pubitemid 17221789)
6. Cassidy J, Duncan R, Morrison GJ, Strohalm J, Plocova D, Kopecek J, Kaye S (1989) Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol 38:875-879 (Pubitemid 19074656)
7. Maeda H, Matsumura Y (2011) EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev 63(3):129-130
8. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Srohalm J, Ulbrich K, Duncan R (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 31(5):766-770
9. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Terada Y, Kano MR, Miyazono K, Uesaka M, Nishiyama N, Kataoka K (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6(12):815-823
10. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653-664
11. Vasey P, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res 5:83-94 (Pubitemid 29045181)
12. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbi A, Burtles S, Duncan R, Cassidy J (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34(6):1629-1636
13. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JSW (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243-254 (Pubitemid 32183025)
14. Loadman PM, Bibby MC, Double JA, Al-Shakhaa WM, Duncan R (1999) Pharmacokinetics of PK1 and doxorubicin in experimental colon tumour models with differing responses to PK1. Clin Cancer Res 5:3682-3688
15. Seymour LW, Ulbrich K, Styger PS, Brereton M, Subr V, Strohalm J, Duncan R (1994) Tumour tropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Brit J Cancer 70:636-641 (Pubitemid 24305589)
16. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:623-630 (Pubitemid 351787307)
17. Fiebig HH and Burger AM (Eds) (1999) Relevance of tumour models in anticancer drug development. Contribution to Oncology, Basel: Karger
18. UKCCCR United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd Ed) (1998) Br J Cancer 77:1-10
19. Harada M, Takeuchi M, Fukao T, Katagiri K (1971) A simple method for the quantitative extraction of dye extravasated into the skin. J Pharm Pharmacol 23:218-219
20. Wedge SR (1991) Mechanism of action of polymer anthracyclines: potential to overcome multidrug resistance. PhD Thesis, Keele University, UK
21. Fraier D, Frigerio E, Pianezzola E, Strolin Benedetti M, Cassidy J, Vasey P (1995) A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone in human plasma and urine by reverse phase HPLC with fluorometric detection. J Pharm Biomed Anal 13:625-631
22. Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11:971-981 (Pubitemid 40175744)
23. Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10:241-253
24. Duncan R, Richardson SCW (2013) Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol Pharm 9:2380-2402
25. Nagy JA, Chang S-H, Dvorak AM, Dvorak HF (2009) Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100:865-869
26. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK (2011) Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Ann Rev Chem Biomol Eng 2:281-298
27. Paterson AH, McCready VR (1975) Tumour imaging radiopharmaceuticals. Br J Radiol 48(571):520-531
28. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H (1998) Early phase tumour accumulation of macromolecules: a great difference in clearance rate between tumour and normal tissues. Jap J Cancer Res 89:307-314 (Pubitemid 28197296)
29. Sat YN (1999) Factors that influence tumour targeting by the enhanced permeability and retention (EPR) effect. PhD Thesis, University of London, UK
30. Sat YN, Burger AM, Fiebig HH, Sausville EA, Duncan R (1999) Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer-doxorubicin (PK1) in human tumour xenografts. Proc Am Assoc Cancer Res 90:41
31. 111In-DTPA-labeled stealth liposomes (IDLSL) in a tumour xenograft model. Br J Cancer 78 (S2):35 (P25)
32. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N, Helidonis ES (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 17(11):3512-3521 (Pubitemid 29517922)
33. Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6:764-775 (Pubitemid 44450465)
34. De Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F (1974) Lysosomotropic agents. Biochem Pharmacol 23:2495-2531
35. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discovery 2(5):347-360. 2805 (Pubitemid 37361705)
36. Chipman SD, Oldham FB, Pezzoni G, Singer JW (2006) Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine 1(4):375-383
37. Satchi R, Connors TA, Duncan R (2001) PDEPT: Polymer directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Brit J Cancer 85:1070-1076 (Pubitemid 33016011)
38. Seib FP, Jones AT, Duncan R (2006) Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation of B16F10 cells and use to study the intracellular fate of HPMA copolymer-doxorubicin. J Drug Targeting 14:375-390 (Pubitemid 44203518)
39. Nugent LJ, Jain RK (1984) Extravascular diffusion in normal and neoplastic tissues. Cancer Res 144:238-244 (Pubitemid 14177745)
40. Mosesson Y, Mills GB, Yarden Y (2008) Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8:835-850
41. Rothberg JM, Sameni M, Moin K, Sloane BF (2012) Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochim Biophys Acta 1824(1):123-132
42. Melancon MP, Wang W, Wang Y, Shao R, Ji X, Gelovani JG, Li C (2007) A novel method for imaging in vivo degradation of poly(l-glutamic acid), a biodegradable drug carrier. Pharm Res 24:1217-1224 (Pubitemid 46798898)
43. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73:2412-2417